Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

Abbas, Mohamed

doi:10.3390/polym13071051

Cited by 35 publications

(12 citation statements)

References 123 publications

(148 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, β-amyloid fibril formation was observed and it was found that TiO 2 -NPs could promote β-amyloid fibrillation by shortening the nucleation process, which is the key rate-determining step of fibrillation [ 57 ]. Thus, the potential role of nanoparticles in treating the accumulation of amyloid-beta peptide in Alzheimer’s patients was reviewed.It was noticed that the nanoparticles from three different categories, i.e., polymer, lipid, and gold nanoparticles, could prevent the accumulation of β-amyloid during the efficient delivery of the drug to the cells to treat Alzheimer’s disease [ 58 ].…”

Section: Resultsmentioning

confidence: 99%

Influence of TiO2 and ZnO Nanoparticles on α-Synuclein and β-Amyloid Aggregation and Formation of Protein Fibrils

et al. 2022

View full text Add to dashboard Cite

The most common neurological disorders, i.e., Parkinson’s disease (PD) and Alzheimer’s disease (AD), are characterized by degeneration of cognitive functions due to the loss of neurons in the central nervous system. The aggregation of amyloid proteins is an important pathological feature of neurological disorders.The aggregation process involves a series of complex structural transitions from monomeric to the formation of fibrils. Despite its potential importance in understanding the pathobiology of PD and AD diseases, the details of the aggregation process are still unclear. Nanoparticles (NPs) absorbed by the human circulatory system can interact with amyloid proteins in the human brain and cause PD. In this work, we report the study of the interaction between TiO2 nanoparticles (TiO2-NPs) and ZnO nanoparticles (ZnO-NPs) on the aggregation kinetics of β-amyloid fragment 1-40 (βA) and α-synuclein protein using surface-enhanced Raman spectroscopy (SERS) and tip-enhanced Raman spectroscopy (TERS). The characterizations of ZnO-NPs and TiO2-NPs were evaluated by X-ray diffraction (XRD) spectrum, atomic force microscopy (AFM), and UV-Vis spectroscopy. The interaction of nanoparticles with amyloid proteins was investigated by SERS. Our study showed that exposure of amyloid protein molecules to TiO2-NPs and ZnO-NPs after incubation at 37 °C caused morphological changes and stimulated aggregation and fibrillation. In addition, significant differences in the intensity and location of active Raman frequencies in the amide I domain were found. The principal component analysis (PCA) results show that the effect of NPs after incubation at 4 °C does not cause changes in βA structure.

show abstract

Section: Resultsmentioning

confidence: 99%

Influence of TiO2 and ZnO Nanoparticles on α-Synuclein and β-Amyloid Aggregation and Formation of Protein Fibrils

et al. 2022

View full text Add to dashboard Cite

show abstract

“…However, these small molecules and natural products are limited by fast hepatic metabolism and poor BBB permeation [219]. Nanotechnology offers the advantage over the conventional therapeutic approaches by stabilizing drugs to cross the BBB and exhibit a superior pharmacotherapeutic effect [220]. However, this is not always the case.…”

Section: Discussionmentioning

confidence: 99%

Mechanisms Involved in Microglial-Interceded Alzheimer’s Disease and Nanocarrier-Based Treatment Approaches

Shadab

Alhakamy

Alfaleh

et al. 2021

JPM

View full text Add to dashboard Cite

Alzheimer’s disease (AD) is a common neurodegenerative disorder accountable for dementia and cognitive dysfunction. The etiology of AD is complex and multifactorial in origin. The formation and deposition of amyloid-beta (Aβ), hyperphosphorylated tau protein, neuroinflammation, persistent oxidative stress, and alteration in signaling pathways have been extensively explored among the various etiological hallmarks. However, more recently, the immunogenic regulation of AD has been identified, and macroglial activation is considered a limiting factor in its etiological cascade. Macroglial activation causes neuroinflammation via modulation of the NLRP3/NF-kB/p38 MAPKs pathway and is also involved in tau pathology via modulation of the GSK-3β/p38 MAPK pathways. Additionally, microglial activation contributes to the discrete release of neurotransmitters and an altered neuronal synaptic plasticity. Therefore, activated microglial cells appear to be an emerging target for managing and treating AD. This review article discussed the pathology of microglial activation in AD and the role of various nanocarrier-based anti-Alzeihmenr’s therapeutic approaches that can either reverse or inhibit this activation. Thus, as a targeted drug delivery system, nanocarrier approaches could emerge as a novel means to overcome existing AD therapy limitations.

show abstract

“…The delicate balance between nerve connections, spinal cord, and the control center, the brain, is easily perturbed by exogenous insults and endogenous degenerative conditions. Debilitating disorders of the central nervous system (CNS) include Alzheimer's disease (AD) [17] and variants of dementia such as Lewy body dementia (LBD), tumors such as neuroblastoma and glioblastoma [18], as well as dyskinesia-related conditions such as Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) [19]. Alzheimer's disease is a type of neurodegenerative disease that is described by the formation of plaques with tangled neurofibers composed of amyloid and tau proteins.…”

Section: Nano-phytopharmaceuticals In Neurological (Cns) Disordersmentioning

confidence: 99%

Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications

et al. 2022

View full text Add to dashboard Cite

Phytopharmaceuticals have been widely used globally since ancient times and acknowledged by healthcare professionals and patients for their superior therapeutic value and fewer side-effects compared to modern medicines. However, phytopharmaceuticals need a scientific and methodical approach to deliver their components and thereby improve patient compliance and treatment adherence. Dose reduction, improved bioavailability, receptor selective binding, and targeted delivery of phytopharmaceuticals can be likely achieved by molding them into specific nano-formulations. In recent decades, nanotechnology-based phytopharmaceuticals have emerged as potential therapeutic candidates for the treatment of various communicable and non-communicable diseases. Nanotechnology combined with phytopharmaceuticals broadens the therapeutic perspective and overcomes problems associated with plant medicine. The current review highlights the therapeutic application of various nano-phytopharmaceuticals in neurological, cardiovascular, pulmonary, and gastro-intestinal disorders. We conclude that nano-phytopharmaceuticals emerge as promising therapeutics for many pathological conditions with good compliance and higher acceptance.

show abstract

Potential Role of Nanoparticles in Treating the Accumulation of Amyloid-Beta Peptide in Alzheimer’s Patients

Cited by 35 publications

References 123 publications

Influence of TiO2 and ZnO Nanoparticles on α-Synuclein and β-Amyloid Aggregation and Formation of Protein Fibrils

Influence of TiO2 and ZnO Nanoparticles on α-Synuclein and β-Amyloid Aggregation and Formation of Protein Fibrils

Mechanisms Involved in Microglial-Interceded Alzheimer’s Disease and Nanocarrier-Based Treatment Approaches

Precision and Advanced Nano-Phytopharmaceuticals for Therapeutic Applications

Contact Info

Product

Resources

About